nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-BD234A1D·Framework v5.0·Pipeline v0.3·Evaluated 18 May 2026·OECD: 1.6 Biological Sciences·Subfield: Genetics·Basis: Full text·Type: Dataset or benchmark paper

An integrated map of genetic variation from 1,092 human genomes.

1000 Genomes Project Consortium et al.1000 Genomes Project Consortium, Abecasis, Auton et al.·2012·Nature·10.1038/nature11632 ↗

In brief

A landmark resource paper that delivers transformative scale and rigorous validation, with population coverage as its principal constraint.

ReliabilityCaveats3 of 4 checks completeRead the entry ↓
Abstract

By characterizing the geographic and functional spectrum of human genetic variation, the 1000 Genomes Project aims to build a resource to help to understand the genetic contribution to disease. Here we describe the genomes of 1,092 individuals from 14 populations, constructed using a combination of low-coverage whole-genome and exome sequencing. By developing methods to integrate information across several algorithms and diverse data sources, we provide a validated haplotype map of 38 million single nucleotide polymorphisms, 1.4 million short insertions and deletions, and more than 14,000 larger deletions. We show that individuals from different populations carry different profiles of rare and common variants, and that low-frequency variants show substantial geographic differentiation, which is further increased by the action of purifying selection. We show that evolutionary conservation and coding consequence are key determinants of the strength of purifying selection, that rare-variant load varies substantially across biological pathways, and that each individual contains hundreds of rare non-coding variants at conserved sites, such as motif-disrupting changes in transcription-factor-binding sites. This resource, which captures up to 98% of accessible single nucleotide polymorphisms at a frequency of 1% in related populations, enables analysis of common and low-frequency variants in individuals from diverse, including admixed, populations.

Strengths · Limitations

Strengths

#methodological rigour

Rigorous FDR validation with transparent limitation reporting

Validation using frequency-matched external data across all variant types, with honest disclosure of the initial high indel FDR (27/76 = 35.5%) and the subsequent application of additional filters reducing it to 5.4%. This level of self-critical transparency strengthens confidence in the resource quality.

↳ Table S6; Supplementary Information; main text validation paragraphs

#contribution

Comprehensive rare-variant characterization advancing the field

The resource fills a documented gap: only 13% of variants below 0.5% frequency and 62% of variants in the 0.5-5% range had been previously described. The resource enables analysis at frequency strata that were inaccessible with prior tools, with 99.3% power to detect SNPs at 1% frequency.

↳ Abstract; Distribution of variation section; UK10K comparison

#application pathway

Immediate operational utility with quantified performance

The resource was already in active use for exome variant screening and GWAS imputation at publication. Imputation accuracy of 90-95% for common variants in non-African populations is documented and comparable to high-quality benchmark haplotypes, with a 25% increase over the Pilot Phase and >2-fold over HapMap.

↳ Uses of 1000 Genomes Project Data in Medical Genetics; Figs. 5a, S14a-c

Limitations

#methodological rigour

Methods detail deferred to supplementary materials

The Methods Summary states only that 'All details concerning sample collection, data generation, processing and analysis can be found in the Supplementary Information.' This limits independent assessment of analytical choices from the main paper alone, though this was standard practice for Nature papers of this era.

↳ Methods Summary

#application pathway

Limited coverage for underrepresented populations

Coverage drops substantially for populations not closely related to those studied. For example, the resource includes only 76.9% of SNPs at 1% frequency in the isolated Sardinian population, compared to 98% in UK-sampled genomes. This limits the resource's utility for population-specific analyses in underrepresented groups.

↳ SardiNIA comparison paragraph; Discussion

#methodological rigour

Ethics and COI documentation not visible in main text

Ethics approval for sample collection and conflict of interest disclosures are not explicitly stated in the available main text. While this documentation would typically appear in supplementary materials for a large consortium paper of this era, its absence from the main text limits verification of research conduct standards.

↳ Methods Summary

Does this match your read? Add your assessment ↓

Nabu Commentary

This paper scores consistently high across all quality dimensions and impact potential components, reflecting its status as a landmark resource in human genetics. The integrated haplotype map of 38 million SNPs across 14 populations filled a well-documented gap in low-frequency variant characterization, and the paper's honest reporting of validation challenges — particularly the initial high indel FDR that required remediation — exemplifies transparent scientific practice. The main quality limitations are era-appropriate: the brief Methods Summary that defers to supplementary materials and the absence of code release were standard for Nature papers in 2012. The modest divergence in impact assessment centered on whether the resource constitutes 'deployment-ready infrastructure' or 'enabling research tool' — it clearly functions as both, with documented imputation accuracy benchmarks and active use at publication, though it is not a clinical intervention per se. Population coverage limitations, particularly for isolated populations like Sardinia, represent the single most substantive constraint on the resource's scope and were honestly documented by the authors themselves.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.5±0.1

Contribution
4.7

The resource substantially extended the characterization of low-frequency (0.5-5%) and rare (<0.5%) variants, with only 62% and 13% of those categories previously described. The integrated haplotype map of 38M SNPs, 1.4M indels, and 14K large deletions, validated with quantified FDRs, provided a resource of immediate and enduring utility for the genetics community.

Abstract; Results on distribution of variation; UK10K comparison

only 62% of variants in the range 0.5-5% and 13% of variants with frequency ≤ 0.5% had been described previously

Methodological Rigour
4.4

The multi-technology integration (low-coverage WGS, deep exome, SNP arrays) with machine-learning-based quality ranking is well-justified and rigorously validated, including honest reporting of the initial high indel FDR (27/76) and subsequent remediation. The Methods Summary is extremely brief in the main text, deferring all procedural detail to supplementary materials, which limits reproducibility assessment from the main paper alone.

Constructing an Integrated Map of Variation; Methods Summary; Table S6

The initial indel call-set was found to have a high FDR (27/76), which led to the application of additional filters

Reporting
4.3

The paper communicates a resource of enormous complexity through a logical flow from resource construction to population genetics to medical genetics applications, with the Box and Figure S1 effectively summarizing the integrated pipeline. Some sections (e.g., functional spectrum analysis) are dense and require domain expertise, appropriate for the target audience.

Abstract; Box; section headers and Results/Discussion narrative
Positioning
4.5

The paper explicitly compares its resource to HapMap, the Pilot Phase, UK10K, and SardiNIA, quantifying the incremental advance at each frequency stratum. Limitations around isolated populations, structural variants, and the inaccessible genome are discussed substantively rather than performatively.

Opening paragraphs; Discussion; UK10K and SardiNIA comparisons

our resource includes only 23.7%, 76.9% and 99.3% of the SNPs with frequencies of ~0.1%, 1.0% and 5.0% respectively in ~2,000 genomes sequenced in a study of the isolated population of Sardinia

Reliability

Caveats3 of 4 checks


Internal CoherenceClean

The paper is internally consistent across abstract, main text, tables, and figures. Key quantitative claims (38 million SNPs, 1.4 million indels, 14,000 large deletions) are stated consistently throughout, and the FDR estimates are reported with appropriate nuance including honest disclosure of the initial high indel FDR.

Research ConductNoted

Data availability is clearly claimed and the resource was publicly available via the 1000genomes.org website. However, ethics approval and COI disclosure are not explicitly stated in the available text, and data hosting is via project websites rather than a persistent repository with formal identifiers.

Flags: 1 declared / 5 total

Reference IntegrityPending

Not yet checked.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
CitationsFWCI 587.0
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The variant catalogue and haplotypes were validated against independent external datasets (UK10K, SardiNIA, trio phasing, orthogonal validation sequencing) and imputation accuracy was benchmarked, but routine operation of Phase 1 itself is not yet demonstrated.

From the paper
“A second major use of the 1000 Genomes Project data in medical genetics is imputing genotypes in existing genome-wide association studies”

The paper names the medical genetics and GWAS research communities and the specific purposes (variant screening in genetic disorders and cancer, genotype imputation, fine-mapping) for which these findings would be used.

Pathway

Medical geneticists and GWAS researchers would use the public haplotype catalogue to filter pathological candidate variants and impute genotypes, accelerating discovery of disease-associated variants.

Barrier

Coverage is lower for populations not closely related to those sampled, and low-complexity and structurally diverse genome regions remain inaccessible, limiting completeness for some users.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry

    Skelton, Mitchell, Assary, et al. · 2026 · Clinical medicine

    Primary claim

    We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety.

    Well-supported
    Evidence Score
    4.0±0.2
    Reliability
    Caveats
  2. Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes

    Rossi, Sportelli, Kikidis, et al. · 2026 · Clinical medicine

    Primary claim

    Applying this framework to Psychiatric Genomics Consortium wave 3 genotypes identified 766 genes associated with schizophrenia

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. Shared proteomic landscape between arteriosclerosis and cardiovascular endpoints: a Mendelian randomization and observational study integrating AlphaFold3 for structural prediction

    Huang, Meena, Achtari, et al. · 2026 · Clinical medicine

    Primary claim

    We prioritized 10 proteins potentially causally associated with both the arteriosclerotic/atherosclerotic markers and cardiovascular events.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →